DIA 48th Annual Meeting
Click here to go to the previous page
Planning Your Drug's Development Life Cycle
Track
:
Track 02: Project/Portfolio Management and Strategic Planning
Program Code:
243
Date:
Tuesday, June 26, 2012
Time:
1:30 PM to 3:00 PM
EST
CHAIR
:
Gregg Schneider, Otsuka Pharmaceutical, United States
PRESENTER
(S):
Scott Simmons, Eli Lilly and Company, United States Badri Rengarajan, Archimedes, United States Vladimir Shnaydman, ORBee Consulting, United States
Description
This symposium will focus on issues surrounding a drug's development life cycle, the use of simulation modeling to enhance development strategy and portfolio decision making, as well as new approaches in portfolio risk assessment and mitigation.
Learning Objectives:
Identify processes to generate a list of potential development pathways
Recognize how simulation models can enhance development strategy and portfolio decision making
Analyze new approaches in portfolio risk assessment and mitigation.
Learning Objectives:
Identify processes to generate a list of potential development pathways
Recognize how simulation models can enhance development strategy and portfolio decision making
Analyze new approaches in portfolio risk assessment and mitigation.
This session is a part of:
Handout Online
